Awaiting News of New Partnerships30 Sep 2024 23:30
Seems like they are gearing up for an expansion of partnerships. Could this offering by GPL cross over into numerous companies within the healthcare industry.
One key future area of focus for the Company will be to seek commercial opportunities for its patented self-nanoemulsifying drug delivery systems ("SNEDDS") platform in the healthcare industry, to enhance the bioavailability, pharmacokinetics, and stability of biopharmaceutical companies' therapeutics.
Hopefully Purcell believes that snedds can be offered to a wide range of companies with very different products.
From the latest rns it sounds as if Dennis and Nicholas are confident of more companies coming aboard.
Nicholas Nelson said As Chairman, Mr. Purcell will guide the Company's collaborations, the first of which is with Awakn Life Sciences Corp. ("Awakn"), a biotechnology company focused on addiction and mental health. This partnership aims to co-develop a new class of medicines for the treatment of trauma-related mental health disorders, including Post-Traumatic Stress Disorder ("PTSD"). Mr Purcell was a Special Adviser to the CEO for Awakn for a short period during 2022.
Dennis Purcell commented: "I am thrilled to join Graft Polymer's Board at such an exciting juncture. The Company's collaboration model, starting with Awakn, is poised to make a significant impact in the biopharmaceutical sector - specifically in the area of treating addiction and mental health issues, where there is an enormous opportunity. I look forward to working closely with my fellow Board members and the management team to drive growth, enhance shareholder value, and bring transformational solutions to patients in need."
Sign In
Follow the stocks
